CU23529A1 - Combinación de egf/ghrp-6 para la neuroregeneración del sistema nervioso central posterior al dano autoinmune - Google Patents
Combinación de egf/ghrp-6 para la neuroregeneración del sistema nervioso central posterior al dano autoinmuneInfo
- Publication number
- CU23529A1 CU23529A1 CU20050043A CU20050043A CU23529A1 CU 23529 A1 CU23529 A1 CU 23529A1 CU 20050043 A CU20050043 A CU 20050043A CU 20050043 A CU20050043 A CU 20050043A CU 23529 A1 CU23529 A1 CU 23529A1
- Authority
- CU
- Cuba
- Prior art keywords
- nervous system
- central nervous
- neuroregeneration
- autoinmune
- ghrp
- Prior art date
Links
- 210000003169 central nervous system Anatomy 0.000 title abstract 3
- 230000035771 neuroregeneration Effects 0.000 title abstract 2
- WZHKXNSOCOQYQX-FUAFALNISA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 WZHKXNSOCOQYQX-FUAFALNISA-N 0.000 title 1
- 108010015153 growth hormone releasing hexapeptide Proteins 0.000 title 1
- 208000016192 Demyelinating disease Diseases 0.000 abstract 1
- 206010012305 Demyelination Diseases 0.000 abstract 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 abstract 1
- 101800003838 Epidermal growth factor Proteins 0.000 abstract 1
- 102000018997 Growth Hormone Human genes 0.000 abstract 1
- 108010051696 Growth Hormone Proteins 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 229940116977 epidermal growth factor Drugs 0.000 abstract 1
- 239000000122 growth hormone Substances 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Zoology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención es dirigida a estimular la neuroregeneración del sistema nervioso central debido al dano autoinmune. En particular la combinación farmacéutica que comprende concentraciones terapéuticamente efectivas del Factor de Crecimiento Epidérmico y del Hexapéptido Secretagogo de la Hormona de Crecimiento Humana es administrada a un sujeto que sufre de los síntomas de Esclerosis Múltiple y Neuromielitis Óptica y corrige la desmielinización causada por células autoreactivas en el Sistema Nervioso Central.
Priority Applications (18)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20050043A CU23529A1 (es) | 2005-03-02 | 2005-03-02 | Combinación de egf/ghrp-6 para la neuroregeneración del sistema nervioso central posterior al dano autoinmune |
| AU2006220154A AU2006220154B2 (en) | 2005-03-02 | 2006-02-24 | Combination of EGF/GHRP-6 for neurogeneration of central nervous system |
| PCT/CU2006/000001 WO2006092106A2 (es) | 2005-03-02 | 2006-02-24 | Combinación de egf/ghrp-6 para la neuroregeneracion del sistema nervioso central posterior al daño autoinmune. |
| MYPI20060792A MY142494A (en) | 2005-03-02 | 2006-02-24 | Combination of egf/ghrp-6 for neuroregeneration of central nervous system following autoimmune damage |
| AT06705745T ATE431743T1 (de) | 2005-03-02 | 2006-02-24 | Kombination von egf/ghrp-6 für die neuroregeneration des zentralnervensystems |
| BRPI0607844A BRPI0607844B8 (pt) | 2005-03-02 | 2006-02-24 | uso do egf e ghrp-6 |
| MX2007010717A MX2007010717A (es) | 2005-03-02 | 2006-02-24 | Combinacion de egf/ghrp-6 para la neuroregeneracion del sistema nervioso central posterior al dano autoinmune. |
| CN2006800139592A CN101180044B (zh) | 2005-03-02 | 2006-02-24 | 用于自身免疫损伤后中枢神经系统神经再生的egf/ghrp-6组合 |
| RU2007136280/15A RU2403913C2 (ru) | 2005-03-02 | 2006-02-24 | Комбинация egf/ghrp-6 для нейрорегенерации центральной нервной системы после аутоиммунного повреждения |
| EP06705745A EP1870106B1 (en) | 2005-03-02 | 2006-02-24 | Combination of egf/ghrp-6 for neuroregeneration of central nervous system |
| JP2007557312A JP5001180B2 (ja) | 2005-03-02 | 2006-02-24 | 自己免疫障害後の中枢神経系の神経再生に用いるｅｇｆ／ｇｈｒｐ−６の組合せ |
| KR1020077022024A KR101255200B1 (ko) | 2005-03-02 | 2006-02-24 | 자가면역 손상에 따른 중추 신경계의 신경 재생용ｅｇｆ/ｇｈｒｐ-6의 조합 |
| PT06705745T PT1870106E (pt) | 2005-03-02 | 2006-02-24 | Combinação de egf/ghrp-6 para a neurorregeneração do sistema nervoso central |
| CA2600628A CA2600628C (en) | 2005-03-02 | 2006-02-24 | Combination of egf/ghrp-6 for neurogeneration of central nervous system following autoimmune damage |
| DE602006006903T DE602006006903D1 (de) | 2005-03-02 | 2006-02-24 | Kombination von egf/ghrp-6 für die neuroregeneration des zentralnervensystems |
| ES06705745T ES2327562T3 (es) | 2005-03-02 | 2006-02-24 | Combinacion de egf/ghrp-6 para la neurorregeneracion del sistema nervioso central. |
| US11/885,330 US20100093616A1 (en) | 2005-03-02 | 2006-02-24 | Combination of EGF/GHRP-6 for Neurogeneration of Central Nervous System Following Autoimmune Damage |
| ZA200707020A ZA200707020B (en) | 2005-03-02 | 2007-08-21 | Combination of EGF/GHRP-6 for neuroregeneration of central nervous system following autoimmune damage |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20050043A CU23529A1 (es) | 2005-03-02 | 2005-03-02 | Combinación de egf/ghrp-6 para la neuroregeneración del sistema nervioso central posterior al dano autoinmune |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CU23529A1 true CU23529A1 (es) | 2010-06-17 |
Family
ID=40280698
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU20050043A CU23529A1 (es) | 2005-03-02 | 2005-03-02 | Combinación de egf/ghrp-6 para la neuroregeneración del sistema nervioso central posterior al dano autoinmune |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20100093616A1 (es) |
| EP (1) | EP1870106B1 (es) |
| JP (1) | JP5001180B2 (es) |
| KR (1) | KR101255200B1 (es) |
| CN (1) | CN101180044B (es) |
| AT (1) | ATE431743T1 (es) |
| AU (1) | AU2006220154B2 (es) |
| BR (1) | BRPI0607844B8 (es) |
| CA (1) | CA2600628C (es) |
| CU (1) | CU23529A1 (es) |
| DE (1) | DE602006006903D1 (es) |
| ES (1) | ES2327562T3 (es) |
| MX (1) | MX2007010717A (es) |
| MY (1) | MY142494A (es) |
| PT (1) | PT1870106E (es) |
| RU (1) | RU2403913C2 (es) |
| WO (1) | WO2006092106A2 (es) |
| ZA (1) | ZA200707020B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA200901077A1 (ru) | 2007-02-09 | 2010-04-30 | Транзим Фарма, Инк. | Макроциклические модуляторы грелинового рецептора и их применение |
| CU24591B1 (es) * | 2018-08-21 | 2022-04-07 | Ct Ingenieria Genetica Biotecnologia | Kit para la restauración del daño cerebral que comprende el factor de crecimiento epidérmico y el hexapéptido secretagogo de la hormona de crecimiento |
| ES2967696T3 (es) | 2019-04-08 | 2024-05-03 | Giuseppe Scalabrino | Factor de crecimiento epidérmico (EGF) y variantes del mismo para tratar o prevenir trastornos desmielinizantes inflamatorios |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9804064D0 (sv) * | 1998-11-25 | 1998-11-25 | A & Science Invest Ab | Medicinal product and method for treatment of conditions affecting neural stem cells or progenitor cells |
| CU23157A1 (es) * | 2001-01-03 | 2006-07-18 | Ct Ingenieria Genetica Biotech | COMPOSICION FARMACéUTICA PARA EL TRATAMIENTO DEL DANO TISULAR DEBIDO A FALTA DE IRRIGACION SANGUINEA ARTERIAL |
| AU2002325712C1 (en) * | 2001-08-30 | 2008-07-31 | Stem Cell Therapeutics Inc. | Differentiation of neural stem cells and therapeutic use theeof |
| HK1077740A1 (en) * | 2001-12-20 | 2006-02-24 | Ct Ingenieria Genetica Biotech | Use of epidermal growth factor in the manufacture of a pharmaceutical injection composition for preventing diabetic limb amputation |
| EP1506997A1 (en) * | 2003-08-14 | 2005-02-16 | NeuroProgen GmbH Leipzig | Method of generating neural stem cells |
-
2005
- 2005-03-02 CU CU20050043A patent/CU23529A1/es active IP Right Grant
-
2006
- 2006-02-24 ES ES06705745T patent/ES2327562T3/es active Active
- 2006-02-24 MY MYPI20060792A patent/MY142494A/en unknown
- 2006-02-24 RU RU2007136280/15A patent/RU2403913C2/ru active
- 2006-02-24 DE DE602006006903T patent/DE602006006903D1/de active Active
- 2006-02-24 WO PCT/CU2006/000001 patent/WO2006092106A2/es active Application Filing
- 2006-02-24 US US11/885,330 patent/US20100093616A1/en not_active Abandoned
- 2006-02-24 AU AU2006220154A patent/AU2006220154B2/en not_active Ceased
- 2006-02-24 EP EP06705745A patent/EP1870106B1/en active Active
- 2006-02-24 AT AT06705745T patent/ATE431743T1/de not_active IP Right Cessation
- 2006-02-24 BR BRPI0607844A patent/BRPI0607844B8/pt not_active IP Right Cessation
- 2006-02-24 CA CA2600628A patent/CA2600628C/en not_active Expired - Fee Related
- 2006-02-24 CN CN2006800139592A patent/CN101180044B/zh active Active
- 2006-02-24 KR KR1020077022024A patent/KR101255200B1/ko active IP Right Grant
- 2006-02-24 MX MX2007010717A patent/MX2007010717A/es active IP Right Grant
- 2006-02-24 PT PT06705745T patent/PT1870106E/pt unknown
- 2006-02-24 JP JP2007557312A patent/JP5001180B2/ja not_active Expired - Fee Related
-
2007
- 2007-08-21 ZA ZA200707020A patent/ZA200707020B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20070107790A (ko) | 2007-11-07 |
| RU2403913C2 (ru) | 2010-11-20 |
| WO2006092106A3 (es) | 2006-12-14 |
| PT1870106E (pt) | 2009-08-25 |
| BRPI0607844A2 (pt) | 2010-10-19 |
| CA2600628A1 (en) | 2006-09-08 |
| KR101255200B1 (ko) | 2013-04-23 |
| RU2007136280A (ru) | 2009-04-10 |
| AU2006220154B2 (en) | 2010-05-27 |
| JP5001180B2 (ja) | 2012-08-15 |
| BRPI0607844B8 (pt) | 2021-05-25 |
| US20100093616A1 (en) | 2010-04-15 |
| AU2006220154A1 (en) | 2006-09-08 |
| MY142494A (en) | 2010-11-30 |
| BRPI0607844B1 (pt) | 2018-08-28 |
| EP1870106A2 (en) | 2007-12-26 |
| ES2327562T3 (es) | 2009-10-30 |
| MX2007010717A (es) | 2007-10-12 |
| CN101180044B (zh) | 2010-12-08 |
| EP1870106B1 (en) | 2009-05-20 |
| DE602006006903D1 (de) | 2009-07-02 |
| CA2600628C (en) | 2013-04-09 |
| JP2008531607A (ja) | 2008-08-14 |
| CN101180044A (zh) | 2008-05-14 |
| ATE431743T1 (de) | 2009-06-15 |
| WO2006092106A2 (es) | 2006-09-08 |
| ZA200707020B (en) | 2009-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FIC20230024I1 (fi) | Farmaseuttisia koostumuksia, jotka käsittävät midatsolaamia suuressa pitoisuudessa | |
| CL2019001079A1 (es) | Métodos para usar indazol-3-carboxamidas y su uso como inhibidores de la vía de señalización de wnt/b-catenina. | |
| CL2018001089A1 (es) | Sales de valbenazina y polimorfos de las mismas. | |
| HN2006013804A (es) | Heteroalrilamidas[3.1.0]biciclicas como inhibidores del trasporte de glicina de tipo i | |
| CU23734A1 (es) | Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas | |
| UY35391A (es) | Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-cianometil)-amidas sustituidas inhibidores de catepsina c | |
| HRP20210543T1 (hr) | Inhibitori pde9 s imidazo triazinonskom okosnicom i imidazo pirazinonskom okosnicom za liječenje perifernih bolesti | |
| NI201000193A (es) | Formulaciones orales de análogos de citidina y métodos de uso de las mismas. | |
| CL2013000368A1 (es) | Compuestos derivados de 6-cicloalquil-1,5-dihidro-pirazolo(3,4-d) pirimidin-4-ona, inhibidores de fosfodiesterasa 9a pde9a; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos y la composicion farmaceutica en la preparacion de un medicamento util en el tratamiento de enfermedades del snc. | |
| BR112015007778A2 (pt) | profármacos neutralizantes de vegf para o tratamento de condições oculares | |
| BR112014009418A2 (pt) | macrociclos peptidomiméticos | |
| BR112014007675A2 (pt) | tratamento de doença articular degenerativa | |
| CL2011002206A1 (es) | Compuestos derivados de benzofurano sustituidos, moduladores del señalador igf1 o activador de la proteina quinasa b; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades del snc, tales como alzheimer, entre otras. | |
| GT201100336A (es) | Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas | |
| AR057239A1 (es) | Inmunoglobulinas | |
| CO2021014694A2 (es) | Una vacuna de subunidad para el tratamiento o la prevención de una infección del tracto respiratorio | |
| BRPI0721984B8 (pt) | interferon-2b peguilado (ifn-2b), seu método de preparo e de purificação, composição, bem como uso dos mesmos | |
| BR112012013164A2 (pt) | composições farmacêuticas para o estímulo de células-tronco | |
| CO7151509A2 (es) | Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1 | |
| CU23529A1 (es) | Combinación de egf/ghrp-6 para la neuroregeneración del sistema nervioso central posterior al dano autoinmune | |
| CL2021003474A1 (es) | Producto farmacéutico para terapia enzimática para tratamiento de homocistinuria | |
| ATE526012T1 (de) | Pharmazeutische formulierungen von meloxicam | |
| ECSP109871A (es) | Soluciones farmacéuticas orales que contienen telbivudina | |
| CO2024002715A2 (es) | Formulaciones de radiprodil | |
| DK1891960T3 (da) | Farmeceutisk formulering til behandling af hudsygdom |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant of patent |